SG11201702954XA - Methods for treating ocular diseases - Google Patents

Methods for treating ocular diseases

Info

Publication number
SG11201702954XA
SG11201702954XA SG11201702954XA SG11201702954XA SG11201702954XA SG 11201702954X A SG11201702954X A SG 11201702954XA SG 11201702954X A SG11201702954X A SG 11201702954XA SG 11201702954X A SG11201702954X A SG 11201702954XA SG 11201702954X A SG11201702954X A SG 11201702954XA
Authority
SG
Singapore
Prior art keywords
methods
ocular diseases
treating ocular
treating
diseases
Prior art date
Application number
SG11201702954XA
Inventor
Margarita Gekkieva
James Warburton
Peter Sallstig
Werner Schmidt
Andreas Weichselberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201702954X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201702954XA publication Critical patent/SG11201702954XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201702954XA 2014-11-07 2015-11-06 Methods for treating ocular diseases SG11201702954XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059575 WO2016073918A1 (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
SG11201702954XA true SG11201702954XA (en) 2017-05-30

Family

ID=54697654

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201702954XA SG11201702954XA (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases
SG11201702909QA SG11201702909QA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody
SG10201913565RA SG10201913565RA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201702909QA SG11201702909QA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody
SG10201913565RA SG10201913565RA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Country Status (24)

Country Link
US (5) US10035850B2 (en)
EP (2) EP3215122A1 (en)
JP (5) JP6667519B2 (en)
KR (3) KR20170082526A (en)
CN (3) CN114081951A (en)
AU (6) AU2015342815B2 (en)
BR (2) BR112017008660A2 (en)
CA (2) CA2966758A1 (en)
CL (2) CL2017001117A1 (en)
CO (1) CO2017004596A2 (en)
EA (1) EA201790989A1 (en)
EC (1) ECSP17034829A (en)
GT (1) GT201700096A (en)
IL (5) IL251642B (en)
MX (3) MX2017005874A (en)
MY (2) MY193913A (en)
NZ (1) NZ730821A (en)
PE (1) PE20170780A1 (en)
PH (2) PH12017500843A1 (en)
RU (1) RU2722643C2 (en)
SG (3) SG11201702954XA (en)
TN (1) TN2017000128A1 (en)
TW (4) TWI761959B (en)
WO (2) WO2016073918A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (en) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Human protein tyrosine phosphatase beta binding antibodies (hptpbeta), and use thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR102007492B1 (en) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 Humanization of rabbit antibodies using a universal antibody framework
HUE039692T2 (en) 2008-06-25 2019-01-28 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting tnf
MX2011007420A (en) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells.
EP4360709A3 (en) 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN104039351A (en) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (en) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド HPTP-β inhibitor
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI761959B (en) 2014-11-07 2022-04-21 瑞士商諾華公司 Methods for treating ocular diseases
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
CN107206080B (en) 2015-01-28 2022-07-08 辉瑞公司 Stable aqueous anti-Vascular Endothelial Growth Factor (VEGF) antibody formulations
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3352856B1 (en) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
CN108712911A (en) 2015-12-30 2018-10-26 科达制药股份有限公司 Antibody and its conjugate
MX2019000727A (en) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Humanized monoclonal antibodies that target ve-ptp (hptp-ãŸ).
CN110248674B (en) * 2016-09-07 2021-10-26 萨辛生命科学有限公司 Synthetic antibodies against VEGF and uses thereof
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
ES2913401T3 (en) 2016-11-18 2022-06-02 Astellas Pharma Inc Novel Fab Fragment of Human Anti-MUC1 Antibody
MX2019011272A (en) 2017-03-22 2019-10-24 Novartis Ag Compositions and methods for immunooncology.
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
WO2018195912A1 (en) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 Ophthalmic pharmaceutical composition and use thereof
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
JP7357609B2 (en) 2017-10-06 2023-10-06 ノボ ノルディスク エー／エス anti-transthyretin antibody
EP3717512A4 (en) * 2017-11-29 2021-08-25 Prothena Biosciences Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CN111699004A (en) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 Treatment of ophthalmic disorders
US20210017266A1 (en) * 2018-03-16 2021-01-21 Novartis Ag Methods for treating ocular diseases
US20210023216A1 (en) * 2018-03-23 2021-01-28 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. Novel angiopoietin 2, vegf dual antagonists
CN112739323A (en) 2018-05-10 2021-04-30 瑞泽恩制药公司 Formulations containing high concentrations of VEGF receptor fusion proteins
CN113164597A (en) 2018-09-24 2021-07-23 爱尔皮奥制药公司 Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
JP7374544B2 (en) * 2018-10-10 2023-11-07 アステラス製薬株式会社 Pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment complex
BR112021007946A2 (en) * 2018-10-29 2021-08-03 F. Hoffmann-La Roche Ag antibody formulation
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
JOP20210152A1 (en) * 2018-12-18 2023-01-30 Novartis Ag Protein solution formulation containing high concentration of an anti-vegf antibody
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
TW202106699A (en) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 Variant aav capsids for intravitreal delivery
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111217834B (en) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Nitroxide derivatives of ROCK kinase inhibitors
CN113698478A (en) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 Anti-alpha-hemolysin antibody and stable formulation thereof
KR20220001106A (en) 2020-06-29 2022-01-05 (주)메디톡스 High concentration anti-VEGF antibody formulation and anti-VEGF antibody for use in the same
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20230302085A1 (en) * 2021-05-17 2023-09-28 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
CN113940997B (en) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 Stable preparation of bispecific antibody
WO2024056058A1 (en) * 2022-09-16 2024-03-21 齐鲁制药有限公司 Stable high-concentration self-buffering pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP2311433A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
CN101478949A (en) * 2006-06-16 2009-07-08 瑞泽恩制药公司 VEGF antagonist formulations suitable for intravitreal administration
PL3216803T3 (en) * 2008-06-25 2020-10-19 Novartis Ag Stable and soluble antibodies inhibiting vegf
EP3130603A1 (en) 2008-06-30 2017-02-15 ESBATech, an Alcon Biomedical Research Unit LLC Functionalized polypeptides
EP4360709A3 (en) * 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
MX2013014687A (en) * 2011-06-30 2014-02-17 Genentech Inc Anti-c-met antibody formulations.
WO2013056851A2 (en) * 2011-10-20 2013-04-25 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
UA117466C2 (en) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
TWI761959B (en) 2014-11-07 2022-04-21 瑞士商諾華公司 Methods for treating ocular diseases
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
IL280087A (en) 2021-03-01
AU2018278870B2 (en) 2020-05-28
RU2017119647A (en) 2018-12-07
EP3215123A1 (en) 2017-09-13
TWI738632B (en) 2021-09-11
PE20170780A1 (en) 2017-07-04
CO2017004596A2 (en) 2017-08-31
SG10201913565RA (en) 2020-02-27
AU2015342818B2 (en) 2019-01-03
KR102588846B1 (en) 2023-10-16
IL265497A (en) 2019-05-30
TWI705827B (en) 2020-10-01
JP6667519B2 (en) 2020-03-18
AU2020220210B2 (en) 2022-01-20
AU2020244614B2 (en) 2023-06-01
RU2020114917A (en) 2020-05-22
AU2018274882B2 (en) 2020-07-09
JP2017538674A (en) 2017-12-28
US20210340242A1 (en) 2021-11-04
US20160340420A1 (en) 2016-11-24
RU2017119647A3 (en) 2019-05-29
JP2017534638A (en) 2017-11-24
RU2722643C2 (en) 2020-06-02
CN107635580A (en) 2018-01-26
IL251696A0 (en) 2017-06-29
TW202103735A (en) 2021-02-01
ECSP17034829A (en) 2019-02-28
IL283561A (en) 2021-07-29
IL283561B (en) 2022-01-01
US10035850B2 (en) 2018-07-31
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
GT201700096A (en) 2019-10-10
IL251642B (en) 2021-02-28
CL2017001117A1 (en) 2018-01-26
AU2018274882A1 (en) 2018-12-20
MX2021006768A (en) 2021-07-15
BR112017008093A2 (en) 2018-03-13
US20180298092A1 (en) 2018-10-18
JP6753848B2 (en) 2020-09-09
EP3215122A1 (en) 2017-09-13
AU2020244614A1 (en) 2020-11-05
CL2017001115A1 (en) 2018-01-26
US20200270336A1 (en) 2020-08-27
MX2017005875A (en) 2017-06-26
RU2020114917A3 (en) 2022-01-17
IL265497B (en) 2021-06-30
TW201625221A (en) 2016-07-16
WO2016073915A1 (en) 2016-05-12
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
TWI806150B (en) 2023-06-21
JP7080263B2 (en) 2022-06-03
TW201625306A (en) 2016-07-16
PH12017500843A1 (en) 2017-10-30
JP2022141923A (en) 2022-09-29
NZ730821A (en) 2019-11-29
AU2020220210A1 (en) 2020-10-01
JP2020193212A (en) 2020-12-03
MX2017005874A (en) 2017-06-26
MY193913A (en) 2022-11-01
KR20170076781A (en) 2017-07-04
JP2020079242A (en) 2020-05-28
IL251642A0 (en) 2017-06-29
PH12017500844B1 (en) 2017-10-30
MY183807A (en) 2021-03-16
BR112017008660A2 (en) 2017-12-26
TWI761959B (en) 2022-04-21
IL280087B (en) 2022-02-01
CN114081951A (en) 2022-02-25
TW202146049A (en) 2021-12-16
US11098110B2 (en) 2021-08-24
KR20230066649A (en) 2023-05-16
PH12017500844A1 (en) 2017-10-30
CA2966646A1 (en) 2016-05-12
KR20170082526A (en) 2017-07-14
US20160130337A1 (en) 2016-05-12
CN106999581A (en) 2017-08-01
EA201790989A1 (en) 2017-09-29
CA2966758A1 (en) 2016-05-12
TN2017000128A1 (en) 2018-10-19
AU2015342815A1 (en) 2017-05-11
WO2016073918A1 (en) 2016-05-12
AU2018278870A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating ocular diseases
HK1231417A1 (en) Compounds for treating ophthalmic diseases and disorders
IL251856B (en) Production method for retinal tissue
HK1246179A1 (en) Methods of treating retinal diseases
IL246791A0 (en) Compositions and methods for treating ocular diseases
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
HK1245127A1 (en) Methods and compositions for treating brain diseases
LT3164394T (en) Gls1 inhibitors for treating diseases
GB201401430D0 (en) Treatment process
HK1258994A1 (en) Methods for treatment of diseases
IL251769A0 (en) Methods of treating ocular conditions
SG11201609522TA (en) Methods for treating cardiovascular diseases
EP3240778A4 (en) Methods and agents for treating disease
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
HK1243937A1 (en) Methods of treating diseases
EP3518913A4 (en) Methods for treating ocular diseases
PL3302463T3 (en) Use of 3-deoxyanthocyanidins for treating ocular diseases
AU2014902334A0 (en) Treatment for myopia